C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
CCCC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
C4 Therapeutics, Inc.NASDAQ: CCCC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$23.33M, compared with -$25.87M a year earlier. Trailing-twelve-month EBITDA was -$100.38M.
Context
- EBITDA amounted to 286.3% of revenue in FY2025, down 4.2 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$62.94M (+38.8%) for the fiscal year ending Dec 2026, a step up from the +0.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.33M-17.0% QoQ
- Last fiscal yearDec 2025
- -$102.91M+0.4% YoY
- LTMMar 2026
- -$100.38M-3.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.8% | -20.1% | -29.9 pp |
| 1 year | +0.4% | +38.8% | +38.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (102.91M) USD
- Year-over-year change
- +0.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (102.91M) | +0.4% |
| FY2024 | 2024-12-31 | (103.37M) | +15.3% |
| FY2023 | 2023-12-31 | (122.1M) | +1.8% |
| FY2022 | 2022-12-31 | (124.28M) | -54.9% |
| FY2021 | 2021-12-31 | (80.26M) | — |
EBITDA vs competitors
How CCCC compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.7% is the 5th highest of 9, against a peer median of +5.6%.
- EBITDA amounts to 287.9% of revenue for CCCC, versus a peer median of 1334.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$22.06M USD | +62.9% | — | 28.2% | |
| LTM Mar 2026 | -$33.82M USD | +24.4% | — | 117.0% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$45.4M USD | +19.5% | — | 2329.5% |
| LTM Mar 2026 | -$61.36M USD | -27.4% | — | 3439.7% | |
| LTM Mar 2026 | -CHF 63.08M CHF | -8.3% | — | — | |
| LTM Mar 2026 | -$75.99M USD | +22.0% | — | — | |
| LTM Mar 2026 | -$100.38M USD | -3.7% | — | 287.9% | |
| LTM Mar 2026 | -$117.46M USD | -66.2% | — | 339.9% | |
| LTM Mar 2026 | -$262.46M USD | -2046.7% | — | 8872.8% | |
| Peer median (excluding CCCC) | — | +5.6% | — | 1334.7% | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.79M | 31.1M | 20.76M | 35.58M | 35.95M |
| Cost of Revenue | 0 | 0 | 7.74M | 0 | 7.98M |
| Gross Profit | 45.79M | 31.1M | 13.02M | 35.58M | 27.97M |
| Gross Margin | 100.0% | 100.0% | 62.7% | 100.0% | 77.8% |
| Research & Development | 94.67M | 117.84M | 117.71M | 110.64M | 104.24M |
| Selling, General & Admin | 33.25M | 42.79M | 42.08M | 42.12M | 36.2M |
| Operating Expenses | 127.92M | 160.63M | 152.05M | 155.2M | 132.46M |
| Depreciation & Amortization | 1.49M | 1.68M | 7.74M | 1.82M | 1.96M |
| EBITDA | (80.26M) | (124.28M) | (122.1M) | (103.37M) | (102.91M) |
| EBITDA Margin | -175.3% | -399.7% | -588.3% | -290.5% | -286.3% |
| Operating Income | (82.13M) | (129.53M) | (139.03M) | (119.61M) | (104.49M) |
| Operating Margin | -179.4% | -416.6% | -669.8% | -336.1% | -290.7% |
| Interest Income | 387K | 3.58M | 9.81M | 14.43M | 10.35M |
| Interest Expense | 2.15M | 2.22M | 1.37M | 0 | 0 |
| Other Income / Expenses | (1.76M) | 1.36M | 7.82M | 14.43M | (384K) |
| Income Before Tax | (83.89M) | (128.18M) | (131.21M) | (105.19M) | (104.87M) |
| Pre-Tax Margin | -183.2% | -412.2% | -632.2% | -295.6% | -291.7% |
| Income Tax Expense | 0 | 0 | 1.28M | 131K | 121K |
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Net Margin | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| EPS (Basic) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| EPS (Diluted) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| Weighted Avg Shares | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
| Weighted Avg Shares (Diluted) | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.